Platelet-activating factor (PAF) receptor expression is associated with histopathological stage and grade and patients' survival in gastric adenocarcinoma

Neoplasma

Volumn 61, Issue 3, 2014, Pages 309-317

  Giaginis, C ^a,b   Kourou, E ^a   Giagini, A ^a   Goutas, N ^a   Patsouris, E ^a   Kouraklis, G ^a   Theocharis, S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

Clinicopathological parameters; Gastric cancer; PAF receptor; Prognosis

Indexed keywords

KI 67 ANTIGEN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; SURVIVAL; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; STOMACH NEOPLASMS;

EID: 84902329759     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_040     Document Type: Article

References (56)

1. DEMOPOULOS CA, PINCKARD RN, HANAHAN DJ. Platelet activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl- 3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254: 9355-9358.
2. PINCKARD RN, MCMANUS LM, DEMOPOULOS CA, HALONEN M, CLARK PO et al. Molecular pathobiology of acetyl glyceryl ether phosphorylcholine: evidence for the structural and functional identity with plateletactivating factor. J Reticuloendothel Soc 1980; 28: 95-103.
3. YOST CC, WEYRICH AS, ZIMMERMAN GA. Te platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010; 92: 692-697. http://dx.doi.org/10.1016/j.biochi.2010.02.011
4. PRESCOTT SM, ZIMMERMAN GA, MCINTYRE TM. Platelet-activating factor. J Biol Chemi 1990; 265: 17381-17384.
5. MELNIKOVA VO, VILLARES GJ, BAR-ELI M. Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron 2008; 1: 103-111. http://dx.doi.org/10.1007/s12307-008-0002-7
6. Camussi G, Montrucchio G, Lupia E, Soldi R, COMOGLIO PM et al. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 1997; 158: 1302-1309.
7. LI T, SOUTHALL MD, YI Q, PEI Y, LEWIS D et al. Te epidermal platelet activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines. J Biol Chem 2003; 278: 16614-16621. http://dx.doi.org/10.1074/jbc.M211287200
8. BRAEUER RR, ZIGLER M, VILLARES GJ, DOBROFF AS, BAR-ELI M. Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol 2011; 21: 83-88. http://dx.doi.org/10.1016/j.semcancer.2010.12.007
9. IZUMI T, SHIMIZU T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995; 1259: 317-333 http://dx.doi.org/10.1016/0005-2760(95)00171-9
10. LUKASHOVA V, ASSELIN C, KROLEWSKI JJ, ROLA-PLESZCZYNSKI M, STANKOVA J. Gprotein- independent activation of Tyk2 by the platelet-activating factor receptor. J Biol Chem 2001; 276: 24113-24121. http://dx.doi.org/10.1074/jbc.M100720200
11. WENTA N, STRAUSS H, MEYER S, VINKEMEIER U. Ty- rosine phosphorylation regulates the partitioning of STAT1 between different dimmer conformations. Proc Natl Acad Sci USA 2008; 105: 9238-9243. http://dx.doi.org/10.1073/pnas.0802130105
12. HE QY, CHEUNG YH, LEUNG SY, YUEN ST, CHU KM et al. Diverse proteomic alteration in gastric adenocarcinoma. Proteomics 2004; 4: 3276-3287. http://dx.doi.org/10.1002/pmic.200300916
13. FORMAN D, BARLEY VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice Res Clin Gastroenterol 2006; 20: 633-649. http://dx.doi.org/10.1016/j.bpg.2006.04.008
14. HOHENBERGER P, GRETSCHEL S. Gastric cancer. Lancet 2003; 362: 305-315. http://dx.doi.org/10.1016/S0140-6736(03)13975-X
15. CHIBA T, MARUSAWA H, USHIJIMA T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterol 2012; 143: 550-563. http://dx.doi.org/10.1053/j.gastro.2012.07.009
16. ZABALETA J. Multifactorial etiology of gastric cancer. Methods Mol Biol. 2012; 863: 411-435. http://dx.doi.org/10.1007/978-1-61779-612-8_26
17. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J et al. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer 2010; 13: 212-221. http://dx.doi.org/10.1007/s10120-010-0568-x
18. VENDRAMINI-COSTA DB, CARVALHO JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012; 18: 3831-3852 http://dx.doi.org/10.2174/138161212802083707
19. HONDA Z-I, ISHII S, SHIMIZU T. Platelet-activating factor receptor. J Biochem 2002; 131: 773-779. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a003164
20. TIEMANN U. Te role of platelet-activating factor in the mammalian female reproductive tract. Reprod Domest Anim. 2008; 43: 647-655. http://dx.doi.org/10.1111/j.1439-0531.2007.00959.x
21. EDWARDS LJ, CONSTANTINESCU CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 2009; 8: 182-190. http://dx.doi.org/10.2174/187152809788681010
22. MELNIKOVA V, BAR-ELI M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev 2007; 26: 359-371. http://dx.doi.org/10.1007/s10555-007-9092-9
23. TSOUPRAS AB, IATROU C, FRANGIA C, DEMOPOULOS CA. Te implication of platelet activating factor in cancer growth and metastasis: potent beneficial roleofPAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009; 9: 390-399. http://dx.doi.org/10.2174/187152609788922555
24. Maggi M, Bonaccorsi L, Finetti G, Carloni V, Muratori M et al. Platelet-activating factor mediates an autocrine prolifera-tive loop in endometrial adenocarcinoma cell line HEC-1A. Cancer Res. 1994; 54: 4777-4784.
25. BUSSOLATI B, BIANCONE L, CASSONI P, RUSSO S, ROLA PLESZCZYNSKI M et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000; 157: 1713-1725. http://dx.doi.org/10.1016/S0002-9440(10)64808-0
26. MANNORI G, BARLETTA E, MUGNAI G, RUGGIERI S. Interaction of tumor cells with vascular endothelia: role of platelet-activating factor. Clin Exp Metastasis 2000; 18: 89-96. http://dx.doi.org/10.1023/A:1026548700247
27. TRIPATHI YB, KANDALA JC, GUNTAKA RV, LIM RW, SHUKLA SD. Platelet-activating factor induces expression of early response genes c-fos and TIS-1 in human epidermoid carcinoma A-431 cells. Life Sci. 1991; 49: 1761-1767. http://dx.doi.org/10.1016/0024-3205(91)90319-7
28. MONTRUCCHIO G, LUPIA E, BATTAGLIA E, DEL SORBO L, BOCCELLINO M. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arterioscl Tromb Vasc Biol 2000; 20: 80-88. http://dx.doi.org/10.1161/01.ATV.20.1.80
29. MONTRUCCHIO G, SAPINO A, BUSSOLATI B, GHISOLFI G, RIZEA-SAVU S et al. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 1998; 153: 1589-1596. http://dx.doi.org/10.1016/S0002-9440(10)65747-1
30. SIROIS MG, EDELMAN ER. VEGF effectonvascular permeability is mediated by synthesis of platelet-activating factor. Am J Physiol. 1997; 272: H2746-H2756.
31. DEO DD, AXELRAD TW, ROBERT EG, MARCHESELLI V, BAZAN NG et al. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. J Biol Chem 2002; 277: 21237-21245. http://dx.doi.org/10.1074/jbc.M110955200
32. ZHANG L, WANG D, JIANG W, EDWARDS D, QIU W et al. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Reprod Biol Endocrinol 2010; 8: 74. http://dx.doi.org/10.1186/1477-7827-8-74
33. ISHII S, NAGASE T, TASHIRO F, IKUTA K, SATO S et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J 1997; 16: 133-142. http://dx.doi.org/10.1093/emboj/16.1.133
34. Biancone L, Cantaluppi V, Del Sorbo L, Russo S, TJOELKER LW et al. Platelet-activating factor inactivation by local expression of platelet-activating factor acetylhydrolase modifies tumor vascularization and growth. Clin Cancer Res 2003; 9: 4214-4220.
35. MELNIKOVA VO, BALASUBRAMANIAN K, VILLARES GJ, DOBROFF AS, ZIGLER M et al. Crosstalk between protease-activated receptor 1 and platelet activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 2009; 284: 28845-28855. http://dx.doi.org/10.1074/jbc.M109.042150
36. Denizot Y, Desplat V, Drouet M, Bertin F, Melloni B. Is there a role of platelet-activating factor in human lung cancer? Lung Cancer 2001; 33: 195-202. http://dx.doi.org/10.1016/S0169-5002(01)00197-0
37. DENIZOT Y, GAINANT A, GUGLIELMI L, BOUVIER S, CUBERTAFOND P et al. Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes'stage of patients. Oncogene 2003; 22: 7222-7224. http://dx.doi.org/10.1038/sj.onc.1207032
38. DENIZOT Y, CHIANEA T, LABROUSSE F, TRUFFINET V, DELAGE M et al. Platelet-activating factor and human thyroid cancer. Eur J Endocrinol. 2005; 153: 31-40. http://dx.doi.org/10.1530/eje.1.01947
39. Pitton C, Lanson M, Besson P, et al. Presence of PAF-acether in human breast carcinoma: relation to axillary lymph node metastasis. J Natl Cancer Inst. 1989; 81: 1298-1302. http://dx.doi.org/10.1093/jnci/81.17.1298
40. APONTE M, JIANG W, LAKKIS M, LI MJ, EDWARDS D et al. Activation of platelet-activating factor receptor and pleio-tropic effectson tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 2008; 68: 5839-5848. http://dx.doi.org/10.1158/0008-5472.CAN-07-5771
41. KITAGAWA D, TAKETOMI A, KAYASHIMA H, KURODA Y, ITOH S et al. Expression of platelet-activating factor receptor: a novel prognosticator in patients with hepatocellular carcinoma following hepatectomy. Oncology 2007; 72: 381-387. http://dx.doi.org/10.1159/000113149
42. Mathonnet M, Descottes B, Valleix D, Truffinet V, Labrousse F et al. Platelet-activating factor in cirrhotic liver and hepatocel-lular carcinoma. World J Gastroenterol 2006; 12: 2773-2778.
43. ONUCHIC AC, MACHADO CML, SAITO RF, RIOS FJ, JANCAR S et al. Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination TerapyinMelanoma. Mediators Inflamm 2012;2012:175408. http://dx.doi.org/10.1155/2012/175408
44. Lauren P. Te two histological main typesofgastric carcinoma: diffuse and so-called intestinal-type carcinoma. Act Pathol Microbiol Scand. 1965; 64: 31-49.
45. SOBIN LH, WITTEKIND C. TNM ClassificationofMalignant Tumors, 5th edition, New York, Wiley-Liss, 1997.
46. GIAGINIS C, DASKALOPOULOU SS, VGENOPOULOU S, SFINIADAKIS I, KOURAKLIS G et al. Heat Shock Pro-tein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol. 2009; 9: 14. http://dx.doi.org/10.1186/1471-230X-9-14
47. GIAGINIS CT, VGENOPOULOU S, TSOUROUFLIS GS, POLITI EN, KOURAKLIS GP et al. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res 2009; 15: 173-181. http://dx.doi.org/10.1007/s12253-008-9120-2
48. GIAGINIS C, GIAGINI A, TSOUROUFLIS G, GATZIDOU E, AGAPITOS E et al. MCM-2 and MCM-5 expression in gastric adenocarcinoma: clinical significance and comparison with Ki-67 proliferative marker. Dig Dis Sci 2011; 56: 777-785. http://dx.doi.org/10.1007/s10620-010-1348-5
49. DENIZOT Y, DESCOTTES B, TRUFFINET V, VALLEIX D, LABROUSSE F et al. Platelet-activating factor and liver metastasis of colorectal cancer. Int J Cancer 2005; 113: 503-505. http://dx.doi.org/10.1002/ijc.20585
50. DENIZOT Y, DE ARMAS R, CAIRE F, POMMEPUY I, TRUFFINET V et al. Platelet-activating factor and human meningiomas. Neuropathol Appl Neurobiol 2006; 32: 674-678. http://dx.doi.org/10.1111/j.1365-2990.2006.00775.x
51. Nigam S, MUller S, Benedetto C. Elevated plasma levels of platelet-activating factor (PAF) in breast cancer patients with hypercalcemia. J Lipid Mediat. 1989; 1: 323-328.
52. Cellai C, Laurenzana A, VANNUCCHI AM, CAPORALE R, PAGLIERANI M et al. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer 2006; 94: 1637-1642.
53. CELLAI C, LAURENZANA A, BIANCHI E, SDELCI S, MAN-FREDINI R et al. Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol 2009; 37: 1176-1185. http://dx.doi.org/10.1016/j.exphem.2009.07.002
54. Darst M, Al-Hassani M, Li T, Yi Q, TRAVERS JM et al. Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J Immunol 2004; 172: 6330-6335.
55. SEO SK, KO HM, KIM HA, CHOI JH, JUN PARK S et al. Platelet-activating factor induces up-regulation of antiapop-totic factors in a melanoma cell line through nuclear factor-κB activation. Cancer Res 2006; 66: 4681-4686. http://dx.doi.org/10.1158/0008-5472.CAN-05-3186
56. DE Oliveira SI, ANDRADE LN, ONUCHIC AC, NO-NOGAKI S, FERNANDES PD et al. Platelet-activating factor receptor (PAF-R)-dependent pathways control tumor growth and tumor response to chemotherapy. BMC Cancer 2010; 10: 200. http://dx.doi.org/10.1186/1471-2407-10-200